QCRBNSET
QuicTPD™ CRBN ligand Set
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.21
packaging
pkg of 50 mg
Quality Level
sustainability
Greener Alternative Product
greener alternative category
storage temp.
2-8°C
General description
5-Amino Thalidomide, Lenalidomide, Pomalidomide and C-5 Lenalidomide are recruiters of CRBN protein that can be leveraged for targeted protein degradation research. They are provided at 50 mg each.
We are committed to bringing you Greener Alternative Products. This product is a Design for Sustainability (DfS) developed product, which belongs to one of the four categories of greener alternatives. Click here to view its DfS scorecard.
Application
Useful for construction of CRBN based partial protacs of full protacs, by utilizing the amine terminus to add suitable linkers with peptide coupling reactions. These can also be used as controls/competitors to confirm target engagement of putative protacs.
Features and Benefits
Quantities provided are sufficient to do at least 96 reactions at 2 micromole each with a D2B approach with a library of suitable bifunctional linkers ending in carboxylic acid terminus to generate a library of partial protacs or full protacs.
Other Notes
CRBN Ligand Set part of QuicTPD™ kit
Legal Information
QuicTPD is a trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Acute Tox. 4 Dermal - Repr. 1A - STOT RE 2
target_organs
Blood
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
Discover QuicTPD™ Acid/Amine Screening Sets for rapid, high-throughput PROTAC® synthesis, streamlining targeted protein degradation research.
Related Content
A webinar to explore the role of the orphan citron rho-interacting kinase (CITK) in cell division and its potential as a target for cancer therapies using proteolysis targeting chimeras (PROTACs).
Aleša Bricelj et al.
ACS medicinal chemistry letters, 12(11), 1733-1738 (2021-11-20)
Proteolysis targeting chimeras (PROTACs) hijacking the cereblon (CRBN) E3 ubiquitin ligase have emerged as a novel paradigm in drug development. Herein we found that linker attachment points of CRBN ligands highly affect their aqueous stability and neosubstrate degradation features. This
Alexandru D Buhimschi et al.
Biochemistry, 57(26), 3564-3575 (2018-06-01)
Inhibition of Bruton's tyrosine kinase (BTK) with the irreversible inhibitor ibrutinib has emerged as a transformative treatment option for patients with chronic lymphocytic leukemia (CLL) and other B-cell malignancies, yet >80% of CLL patients develop resistance due to a cysteine
Georg E Winter et al.
Science (New York, N.Y.), 348(6241), 1376-1381 (2015-05-23)
The development of effective pharmacological inhibitors of multidomain scaffold proteins, notably transcription factors, is a particularly challenging problem. In part, this is because many small-molecule antagonists disrupt the activity of only one domain in the target protein. We devised a
Global Trade Item Number
| SKU | GTIN |
|---|---|
| QCRBNSET-1KT | 04065272377317 |